Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) Other Operating Expenses (2023 - 2026)

Lexeo Therapeutics' Other Operating Expenses history spans 1 years, with the latest figure at $53.1 million for Q4 2023.

  • On a quarterly basis, Other Operating Expenses changed N/A to $53.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $53.1 million, a N/A change, with the full-year FY2025 number at -$37.0 million, down 48.06% from a year prior.
  • Other Operating Expenses hit $53.1 million in Q4 2023 for Lexeo Therapeutics.
  • Over the last five years, Other Operating Expenses for LXEO hit a ceiling of $53.1 million in Q4 2023 and a floor of $53.1 million in Q4 2023.